Incidence of immunosuppression at admission to intensive care unit

Incidence of immunosuppression at admission to intensive care unit - 3III

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012348

Enrollment

150

Registered

2017-04-27

Start date

2017-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Need for intensive care

Interventions

Group 1: Monocyte HLA-DR of patients with indication for intensive care treatment will be assessed once upon admission to ICU

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age >=18 Informed consent First time admission to ICU in current stay

Exclusion criteria

Exclusion criteria: Palliative status

Design outcomes

Primary

Measure	Time frame
Incidence of immunosuppression on ICU admission (<8.000 HLA-DR molecules/monocyte)	—

Secondary

Measure	Time frame
Survival (day 28) ICU stay Hospital stay Microbiological diagnosis of infection (all sites) Days under antibiotics	—

Countries

Germany

Contacts

Public ContactMarkus Alexander Weigand

Klinik für AnästhesiologieUniversitätsklinikum Heidelberg

markus.weigand@med.uni-heidelberg.de00496221566350

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 21, 2026